Cumberland Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cumberland Pharmaceuticals generated cash of $6,093,821, which is less than the previous year. Cash used in financing activities reached the amount of -$7,424,472 last year. Net change in cash is therefore -$1,436,346.
Cash Flow
| 2014 | 6.69M | -6.03M | -1.66M |
|---|---|---|---|
| 2015 | 5.87M | -2.34M | -5.19M |
| 2016 | 569.47K | -3.11M | -1.14M |
| 2017 | -557.71K | 9.51M | 1.94M |
| 2018 | 3.11M | -27.72M | 7.13M |
| 2019 | 3.05M | 2.29M | -5.08M |
| 2020 | 5.41M | -1.75M | -7.11M |
| 2021 | 6.34M | -501.89K | -3.55M |
| 2022 | 8.45M | -13.67M | -2.06M |
| 2023 | 6.09M | -105.69K | -7.42M |
CPIX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 19.75M | 27.04M | 24.75M | 28.21M | 27.93M | 45.41M | 34.51M | 38.20M | 39.86M | 40.86M |
Operating activities | ||||||||||
Net income | -6.27M | -5.65M | -3.60M | -3.41M | -3.54M | -7.03M | -8.04M | -1.00M | 671.10K | 2.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.77M | 5.32M | 4.60M | 4.74M | 4.40M | 2.98M | 2.64M | 2.39M | 2.24M | 1.98M |
Stock-based compensation expense | 365.04K | 447.50K | 741.86K | 1.04M | 1.48M | 0 | 1.48M | 852.10K | 622.50K | 761.66K |
| Deferred income tax benefit | 365.04K | 447.50K | 741.86K | 1.04M | 1.48M | 0 | 1.48M | 852.10K | 622.50K | 761.66K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.40M | -6.11M | 5.50M | -4.51M | -1.39M | 550.86K | -1.06M | -1.25M | -572.39K | -974.30K |
Inventories | -23.14K | 1.37M | 4.81M | 2.13M | 1.10M | 460.50K | -1.36M | -1.10M | 1.33M | 1.53M |
Accounts payable | 3.72M | 15.06M | -757.59K | 6.56M | 3.22M | 4.30M | 2.30M | 191.90K | 1.47M | 2.83M |
Cash generated by operating activities | 6.09M | 8.45M | 6.34M | 5.41M | 3.05M | 3.11M | -557.71K | 569.47K | 5.87M | 6.69M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -200K | 0 | -11.74M | -19.57M | -2.37M | -5.47M | -7.52M | -4.20M |
Investments In Property Plant And Equipment | -453.05K | -2.07M | -354.46K | -2.11M | -1.01M | -4.27M | -1.48M | -2.13M | -2.69M | -3.26M |
Acquisitions Net | 0 | -13.5M | 0 | 0 | -5M | -20M | 1.21M | 2.00M | 2.55M | -2M |
Cash generated by investing activities | -105.69K | -13.67M | -501.89K | -1.75M | 2.29M | -27.72M | 9.51M | -3.11M | -2.34M | -6.03M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | -135.40K | 0 | 200.90K | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -740.53K | -1.05M | -1.38M | -1.85M | -3.49M | -2.87M | -3.72M | -2.52M | -5.33M | -4.31M |
Repayments of term debt | -3.41M | 1.2M | -59M | -62.5M | -1.5M | -45.8M | 5.7M | -2.4M | 1.7M | 0 |
Cash used in financing activities | -7.42M | -2.06M | -3.55M | -7.11M | -5.08M | 7.13M | 1.94M | -1.14M | -5.19M | -1.66M |
Net Change In Cash | -1.43M | -7.28M | 2.28M | -3.45M | 273.67K | -17.47M | 10.90M | -3.69M | -1.66M | -1.00M |
Cash at end of period | 18.32M | 19.75M | 27.04M | 24.75M | 28.21M | 27.93M | 45.41M | 34.51M | 38.20M | 39.86M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |